Discovery of a new genetic syndrome that predisposes the body to cancer

September 22, 2017

A new syndrome caused by biallelic mutations in the FANCM gene predisposes the body to the appearance of tumours and causes rejection to chemotherapy treatments. Contrary to what scientists believed, the gene does not cause Fanconi anaemia. Researchers recommend modifying the clinical monitoring of patients with these mutations.

A study led by Jordi Surrallés, professor of the Department of Genetics and Microbiology at the Universitat Autònoma de Barcelona, director of the Genetics Unit at the Hospital de la Santa Creu i Sant Pau and lead researcher at the Centre for Biomedical Network Research on Rare Diseases (CIBERER), has identified a new genetic syndrome caused by mutations in both copies of the FANCM gene, also known as biallelic mutations. The results, published in Genetics in Medicine, the official journal of the American College of Medical Genetics and part of the Nature group, suggest that these mutations predispose the body to early formations of tumours and chemotherapy toxicity.

In the article, lead author Massimo Bogliolo from the CIBERER research group led by Jordi Surrallés analysed biallelic mutations in the FANCM gene in three individuals. Despite the low number of in similar studies, the early onset of cancer and toxicity to chemotherapy is notable. But the patients did not present any congenital malformations or any haematological phenotype that could sugges Fanconi anaemia, a rare disease affecting one out of every 100,000 children. Until now, it was believed that the FANCM gene was related to this disease, as the biallelic mutation was observed in patients suffering from Fanconi anaemia in 2005.

In another article published in the same volume of the journal, researchers from Dr Surrallés' group and the research group led by Javier Benítez at the CNIO and the CIBERER confirmed that women with biallelic mutations in the FANCM gene did not develop Fanconi anaemia, but did present a higher risk of breast cancer, chemotherapy toxicity and chromosomal fragility.

"Until now, it was thought that biallelic mutations in the FANCM gene caused Fanconi anaemia, but we have now demonstrated that it is not so, given that in the two studies, there were eight patients with these mutations and none of them had anaemia," says Jordi Surrallés. However, the patients had developed cancer at very early ages, and also presented chemotherapy toxicity. Therefore, in view of the new syndrome, the authors recommend modifying the clinical monitoring of patients with biallelic mutations in the FANCM gene and taking precautions when using chemotherapy and radiation therapies due to the acute toxicity they may produce.

Genetic Complementation Test

For the study, the researchers conducted functional complementation tests, mass sequencing analyses in which there are several mutated and it is not clear which ones are the source of the disease. The patient's cells have a clear phenotype of chemical hypersensitivity to DEB, an agent that causes damage to DNA. In contrast, when a healthy FANCM gene copy was transferred into the cells of patients with the help of a virus (using lentiviral transductions), researchers observed the reversal of this phenotype and cells behaving as if they were healthy (a response similar to that of a healthy donor). This functional study is the genetic demonstration that the gene causing the disease is FANCM, and therefore, the observed in this gene are of a pathogenic nature.

Explore further: Researchers discover potential cancer treatment breakthrough

More information: Massimo Bogliolo et al. Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia, GENETICS in MEDICINE (2017). DOI: 10.1038/gim.2017.124

Related Stories

Researchers discover potential cancer treatment breakthrough

August 8, 2017
Patients undergoing conventional chemotherapy for certain cancers could potentially receive more effective and less toxic drug treatment. In a July issue of the journal Proceedings of the National Academy of Sciences (PNAS), ...

Gene controls three different diseases

April 25, 2013
An international research consortium led by the Universitat Autònoma de Barcelona (UAB), the CIBERER and the University of Wurzburg (Germany) has discovered a gene that can cause three totally different diseases, depending ...

Study identifies new gene mutation associated with defective DNA repair and Fanconi anemia

July 10, 2017
Fanconi anemia is a rare genetic disease characterized by hematologic symptoms that include low platelet count and unusually large red blood cells. Mutations in nearly 20 genes have been identified as causative for Fanconi ...

Recommended for you

Association found between abnormal cerebral connectivity and variability in the PPARG gene in developing preterm infants

December 12, 2017
(Medical Xpress)—A team of researchers with King's College London and the National Institute for Health Research Biomedical Research Centre, both in the U.K., has found what they describe as a strong association between ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.